Add Trial
Sign In

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer


Study Type Treatment
Sponsor Name Astrazeneca
Disease type Non-Small Cell Lung Cancer
Disease Stage IB – IIIA
Clinical Status Adjuvant
Phase III
Intervention / Treatment Durvalumab versus Placebo
Research Site Quebec Heart and Lung Institute
Investigator Dre Lise Tremblay
Coordinator Brigitte Fortin
Telephone number
Fax number
Study start date October 9, 2014
Study end date
Trial Status Recruiting
Study Type Treatment, Interventional
Sponsor Name
Tumor Site NSCLC - Non Small Cell Lung Cancer
Disease Stage Stage I, Stage II, Stage III
Clinical Status Adjuvant, Operable
Phase Phase I
Intervention / Treatment
Research Site Quebec, Quebec Heart and Lung Institute
Telephone Number +1 418 656-8711
Fax Number
Study Start Date
Study End Date
Trial Status


Working Hours :

Now Closed UTC - 4
  • MondayDay Off
  • TuesdayDay Off
  • WednesdayDay Off
  • ThursdayDay Off
  • FridayDay Off
  • SaturdayDay Off
  • SundayDay Off

Price / Claim :

Recruit a patient:

*for confidentiality, do not include the name of the patient

*pour raisons de confidentialité, n'incluez pas le nom du patient

Hosted by :

Claim listing: CCTG BR.31

Our website is under development. We're sorry for any inconvenience that might appear.Notre site web est en cours de développement. Nous sommes désolés pour tout inconvénient qui pourrait survenir.

Reply to Message


Account details will be confirmed via email.

Reset Your Password